Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity
JAMA Surgery · 2023
DOI: 10.1001/jamasurg.2023.0252 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Surgery, 2023. Verfasst von Joonas H Kauppila und 4 weiteren Autor:innen. Beteiligte Einrichtung: Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Swede…. Hauptthemen laut MEDLINE: Bariatric Surgery, Gastric Bypass, Obesity, Morbid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Bariatric surgery can resolve hyperlipidemia, cardiovascular disease, and diabetes, but the long-term postoperative trajectories of medications for these conditions are unknown.
Objective
To clarify the long-term use of lipid-lowering, cardiovascular, and antidiabetic medication after bariatric surgery compared with no surgery for morbid obesity. Design, Setting, and Participants This population-based cohort study took place in Sweden (2005-2020) and Finland (1995-2018) and included individuals diagnosed with obesity. Analysis took place between July 2021 and January 2022. Exposures Bariatric surgery (gastric bypass or sleeve gastrectomy) patients using lipid-lowering, cardiovascular, or antidiabetic medication were compared with 5 times as many control patients with an obesity diagnosis treated with no surgery, matched for country, age, sex, calendar year, and medication use. Main Outcomes and Measures Proportions with 95% CIs of lipid-lowering, cardiovascular, or antidiabetic medication.
Results
A total of 26 396 patients underwent bariatric surgery (with gastric bypass or sleeve gastrectomy) (17 521 [66.4%] women; median [IQR] age, 50 [43-56] years) and 131 980 matched control patients (87 605 [66.4%%] women; median [IQR] age, 50 [43-56] years) were included. The proportion of lipid-lowering medication after bariatric surgery decreased from 20.3% (95% CI, 20.2%-20.5%) at baseline to 12.9% (95% CI, 12.7%-13.0%) after 2 years and 17.6% (95% CI, 13.3%-21.8%) after 15 years, while it increased in the no surgery group from 21.0% (95% CI, 20.9%-21.1%) at baseline to 44.6% (95% CI, 41.7%-47.5%) after 15 years. Cardiovascular medications were used by 60.2% (95% CI, 60.0%-60.5%) of bariatric surgery patients at baseline, decreased to 43.2% (95% CI, 42.9%-43.4%) after 2 years, and increased to 74.6% (95% CI, 65.8%-83.4%) after 15 years, while it increased in the no surgery group from 54.4% (95% CI, 54.3%-54.5%) at baseline to 83.3% (95% CI, 79.3%-87.3%) after 15 years. Antidiabetic medications were used by 27.7% (95% CI, 27.6%-27.9%) in the bariatric surgery group at baseline, decreased to 10.0% (95% CI, 9.9%-10.2%) after 2 years, and increased to 23.5% (95% CI, 18.5%-28.5%) after 15 years, while it increased in the no surgery group from 27.7% (95% CI, 27.6%-27.7%) at baseline to 54.2% (95% CI, 51.0%-57.5%) after 15 years. Conclusions and Relevance In this study, undergoing bariatric surgery was associated with a substantial and long-lasting reduction in the use of lipid-lowering and antidiabetic medications compared with no surgery for obesity, while for cardiovascular medications this reduction was only transient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
- Department of Surgery, Oulu University Hospital and University of Oulu, Oulu, Finland.
- Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom.
- School of Cancer and Pharmaceutical Sciences, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, England.
Zitieren
APA
Kauppila, J. H., Markar, S., Santoni, G., Holmberg, D., & Lagergren, J. (2023). Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity. JAMA Surgery. https://doi.org/10.1001/jamasurg.2023.0252
Vancouver
Kauppila JH, Markar S, Santoni G, Holmberg D, Lagergren J. Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity. JAMA Surgery. 2023. doi:10.1001/jamasurg.2023.0252
BibTeX
@article{Kauppila2023,
author = {Kauppila, Joonas H and Markar, Sheraz and Santoni, Giola and Holmberg, Dag and Lagergren, Jesper},
title = {Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity},
journal = {JAMA Surgery},
year = {2023},
doi = {10.1001/jamasurg.2023.0252}
}
EUVIMED